EUVIMEDEUVIMED entdecken
Crossref

A Newly Designed Antibody–drug Conjugate Targeting B7-H3 Demonstrates Enhanced Therapeutic Efficacy Across a Spectrum of Cancers

Jing Qian, Xinyu Zhu, Xiaobei Zhao, Jie Zhu, Zhenhua Wu, Qiaohong Zheng, Jincheng Wang, Feng Yu, Lei Nie, Qinjie Weng

Pharmaceutical Research · 2026

DOI: 10.1007/s11095-026-04076-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Research, 2026. Verfasst von Jing Qian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zh…. Hauptthemen laut MEDLINE: Immunoconjugates, B7 Antigens, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Zhejiang Provincial Natural Science Foundation, General Program of China Postdoctoral Science Foundation, Zhejiang Provincial Selective Funding for Postdocs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The development of antibody-drug conjugates (ADCs) has accelerated due to their tumor-targeting precision. However, challenges in optimizing the target-linker-payload combination often lead to attrition from safety or efficacy issues, highlighting the need for ADCs with an improved therapeutic index. This study presents a newly designed B7-H3-targeted ADC, BR112, and demonstrates its superior preclinical efficacy across multiple models. METHODS: BR112 comprises a humanized anti-B7-H3 antibody (112-59) conjugated to the microtubule inhibitor MMAE via a Pyridazinedione-valine-citrulline-p-aminobenzyl (PD-VC-PAB) linker with a drug-to-antibody ratio (DAR) of 4.15. The binding affinity and internalization profile of 112-59 were evaluated across multiple cell lines. In vitro cytotoxicity and in vivo antitumor efficacy were assessed in multiple cancer cell lines and three xenograft models. Pharmacokinetics of BR112 were analyzed in cynomolgus monkeys. RESULTS: The antibody 112-59 exhibited high binding affinity for human B7-H3 (Kd = 5.28 nM), with potent cell-binding (EC50 ≈ 1 nM) and superior internalization across multiple cancer cell lines, exceeding the performance of antibodies used in clinical-stage comparator ADCs (MGC018 and DS-7300). Consequently, BR112 demonstrated potent cytotoxicity in vitro, with IC50 values ranging from femtomolar to nanomolar. In vivo, BR112 induced complete tumor regression in xenograft models (HCC1954, HCC1806, Calu-6) at doses of 3-10 mg/kg, outperforming both MGC018 and DS-7300. Pharmacokinetic studies in cynomolgus monkeys showed dose-proportional exposure and minimal MMAE release, confirming linker stability. CONCLUSION: This study positions BR112 as a promising therapeutic candidate with enhanced efficacy and a stable pharmacokinetic profile for the treatment of B7-H3-expressing solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesB7 AntigensNeoplasmsAntineoplastic AgentsAntibodies, Monoclonal, HumanizedAnimalsHumansMacaca fascicularisCell Line, TumorXenograft Model Antitumor AssaysFemaleMiceOligopeptidesDrug Design

Stichwörter der Autor:innen

B7-H3BR112anti-tumorantibody–drug conjugate

Substanzen

ImmunoconjugatesB7 AntigensCD276 protein, humanAntineoplastic AgentsOligopeptidesmonomethyl auristatin EAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310007, China.
  • Zhejiang Center for Drug & Cosmetic Evaluation, Hangzhou, China.
  • Taizhou Institute of Zhejiang University, Taizhou, 318000, China.
  • Zhejiang Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • BioRay Pharmaceutical Co.,Ltd., Taizhou, 318000, China.
  • Polytechnic Institute of Zhejiang University, Hangzhou, 310015, China.

Förderung

  • Zhejiang Provincial Natural Science Foundation
  • General Program of China Postdoctoral Science Foundation
  • Zhejiang Provincial Selective Funding for Postdocs

Zitieren

APA

Qian, J., Zhu, X., Zhao, X., Zhu, J., Wu, Z., Zheng, Q., Wang, J., Yu, F., Nie, L., & Weng, Q. (2026). A Newly Designed Antibody–drug Conjugate Targeting B7-H3 Demonstrates Enhanced Therapeutic Efficacy Across a Spectrum of Cancers. Pharmaceutical Research. https://doi.org/10.1007/s11095-026-04076-6

Vancouver

Qian J, Zhu X, Zhao X, Zhu J, Wu Z, Zheng Q, et al. A Newly Designed Antibody–drug Conjugate Targeting B7-H3 Demonstrates Enhanced Therapeutic Efficacy Across a Spectrum of Cancers. Pharmaceutical Research. 2026. doi:10.1007/s11095-026-04076-6

BibTeX
@article{Qian2026,
  author = {Qian, Jing and Zhu, Xinyu and Zhao, Xiaobei and Zhu, Jie and Wu, Zhenhua and Zheng, Qiaohong and Wang, Jincheng and Yu, Feng and Nie, Lei and Weng, Qinjie},
  title = {A Newly Designed Antibody–drug Conjugate Targeting B7-H3 Demonstrates Enhanced Therapeutic Efficacy Across a Spectrum of Cancers},
  journal = {Pharmaceutical Research},
  year = {2026},
  doi = {10.1007/s11095-026-04076-6}
}
Kostenlos starten →